News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
203,243 Results
Type
Article (19568)
Company Profile (109)
Press Release (183566)
Section
Business (65670)
Career Advice (804)
Deals (9532)
Drug Delivery (68)
Drug Development (19339)
Employer Resources (137)
FDA (3493)
Job Trends (6015)
News (98459)
Policy (7386)
Tag
Academia (1495)
Alliances (18214)
Alzheimer's disease (486)
Antibody-drug conjugate (ADC) (45)
Approvals (3456)
Artificial intelligence (72)
Bankruptcy (46)
Best Places to Work (4868)
Biosimilars (41)
Biotechnology (67)
Breast cancer (37)
Cancer (322)
Career advice (709)
Cell therapy (90)
Clinical research (14396)
Collaboration (187)
COVID-19 (960)
C-suite (52)
Data (326)
Diabetes (45)
Diagnostics (2378)
Diversity, equity & inclusion (37)
Drug pricing (39)
Earnings (14767)
Employer resources (117)
Events (29462)
Executive appointments (145)
FDA (3621)
Funding (153)
Gene therapy (68)
GLP-1 (285)
Government (1306)
Healthcare (5110)
Infectious disease (997)
Inflammatory bowel disease (46)
Interviews (112)
IPO (3715)
Job creations (1318)
Job search strategy (627)
Layoffs (143)
Legal (1296)
Lung cancer (60)
Management (41)
Manufacturing (83)
Medical device (2699)
Medtech (2703)
Mergers & acquisitions (5898)
Metabolic disorders (151)
Neuroscience (588)
NextGen Class of 2024 (2096)
Non-profit (1663)
Northern California (451)
Obesity (100)
Opinion (89)
People (26823)
Phase I (4261)
Phase II (5969)
Phase III (5655)
Pipeline (125)
Postmarket research (590)
Preclinical (2398)
Press Release (61)
Radiopharmaceuticals (64)
Rare diseases (69)
Real estate (2594)
Recruiting (53)
Regulatory (5136)
Research institute (1263)
Resumes & cover letters (106)
Southern California (303)
Startups (2027)
United States (3880)
Vaccines (163)
Weight loss (82)
Date
Last 7 days (260)
Last 30 days (987)
Last 365 days (11842)
2024 (10694)
2023 (13328)
2022 (16904)
2021 (18824)
2020 (17045)
2019 (15450)
2018 (11081)
2017 (10697)
2016 (10477)
2015 (11365)
2014 (8408)
2013 (7281)
2012 (7751)
2011 (7878)
2010 (7329)
Location
Africa (324)
Arizona (52)
Asia (11388)
Australia (2076)
California (896)
Canada (393)
China (73)
Colorado (51)
Europe (31875)
Florida (121)
Illinois (93)
Indiana (84)
Maryland (130)
Massachusetts (776)
Michigan (65)
Minnesota (85)
New Jersey (302)
New York (358)
North Carolina (233)
Northern California (451)
Ohio (43)
Pennsylvania (178)
South America (401)
Southern California (303)
Texas (120)
Washington State (84)
203,243 Results for "roivant sciences gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Startups
Roivant Creates New ‘Vant’ to License Bayer’s Pulmonary Hypertension Drug
Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to develop and commercialize mosliciguat, a potential first-in-class inhaled soluble guanylate cyclase activator.
September 10, 2024
·
2 min read
·
Tristan Manalac
M&A
Roivant Deals Again, Sending Dermavant to Organon in Sale Worth Up to $1.2B
The sale of Dermavant clears the way for Roivant to focus on autoimmune-focused Immunovant and a slate of upcoming pivotal trials.
September 18, 2024
·
3 min read
·
Annalee Armstrong
Drug Development
Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung).
April 25, 2024
·
6 min read
Business
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update.
May 30, 2024
·
21 min read
Press Releases
Roivant Provides Update on Graves’ Disease Development Program
September 9, 2024
·
9 min read
Policy
Judge Rules Against Moderna in COVID-19 Patent Fight with Roivant Subsidiary
A Delaware judge on Wednesday agreed with Roivant subsidiary Arbutus and Genevant’s interpretation of specific patent claims regarding the lipid nanoparticle delivery system used by Moderna’s COVID-19 vaccine.
April 4, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
October 29, 2024
·
3 min read
Drug Development
Roivant to Shutter MDS-Focused ‘Vant’ After Disappointing Phase I/II Trial Results
Roivant Sciences will wind down operations for Hemavant, which was formed two years ago to advance RVT-2001 as a potential first-in-class treatment for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes.
February 14, 2024
·
2 min read
·
Tristan Manalac
Business
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provide a business update.
May 16, 2024
·
3 min read
Drug Development
Roivant Posts Phase II Eye Disease Win for TYK2 Drug, Plans Pivotal Program
Roivant has chalked up a mid-stage victory for its Pfizer-partnered dual TYK2/JAK1 inhibitor, setting it up to start a Phase III trial in non-anterior non-infectious uveitis this year.
April 2, 2024
·
2 min read
·
Nick Paul Taylor
1 of 20,325
Next
